TrialESMO open2024

Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial.

J Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.